TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02563587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Accompaniment without causing the laughter of children.
Description: The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
Study: NCT02035904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)
Description: patient controlled infusion from the 2nd day after surgery
Study: NCT02716935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified lipid based nutrient supplement
Description: 6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lipid based nutrient supplement
Description: Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
Study: NCT02953951

Intervention type: OTHER
Intervention: blood transfusion
Description: blood transfusion different sources

Intervention type: OTHER
Intervention: blood transfusion
Description: blood transfusion different sources
Study: NCT00423683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arixtra alone
Description: Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arixtra + filter
Description: Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
Study: NCT01517230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Local radio campaign to reduce under-five child mortality
Description: The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years.
Study: NCT01340105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Study: NCT01097941

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Attenuated H1N1 Influenza Vaccine
Description: 0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A (H1N1) 2009 Monovalent Vaccine
Description: 0.5 ml IM, 2 doses given 28 days apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
Description: 0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
Study: NCT01391741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Cues
Description: Walking with visual cues for 30 minutes, 4 times a week for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking without visual cues
Description: Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
Study: NCT00540293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
Study: NCT02185651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zavesca® Prescription
Description: Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zavesca® Prescription
Description: Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
Study: NCT00521027

Intervention type: DEVICE
Group type: OTHER
Intervention: Versajet Hydrosurgery System
Description: Debridement with Versajet Hydrosurgery System
Study: NCT02035904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: patient controlled infusion from the 2nd day after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine continuous infusion
Description: Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine continuous infusion
Description: Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrawound infusion catheter
Description: placed by surgeon at the end surgery in all patients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intrawound infusion catheter
Description: placed by surgeon at the end surgery in all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine
Description: PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
Study: NCT03323853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARS-SA Summary Results
Description: Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
Study: NCT04199585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF95245
Description: solution, single dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF95245
Description: solution, single dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF95245 14C radiolabelled spiked dosage
Description: solution, single dose, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution, single dose, orally
Study: NCT01087593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 17β-estradiol
Description: Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol
Description: Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
Study: NCT01132703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the Treatment Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the Treatment Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the Treatment Arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the Treatment Arm.
Study: NCT03500289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
Study: NCT02791347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Study: NCT03167138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous micro-fragmented adipose tissue
Description: Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems system
Description: The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
Study: NCT02035904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patrol
Description: tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
Study: NCT00521027

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgical debridement techniques
Description: Conventional surgical debridement with scalpel and pulse lavage
Study: NCT02944383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene tablets administered orally once daily, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Gemcabene tablets administered orally once daily, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally once daily, for 12 weeks.
Study: NCT02245321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate- 19 mg
Description: Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate- 38 mg
Description: Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter Group- Information Provided
Description: Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Letter - No Information Provided
Description: Receive a letter thanking the participant for their participation.
Study: NCT03122067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo
Study: NCT02245321

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive pills to take daily that contain 0 mg iron.
Study: NCT01435174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: A single dose of two oral ranolazine extended release 500 mg tablets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Blood and Dialysate Sampling
Description: Blood samples collected to assess ranolazine plasma and dialysate concentrations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QT Interval
Description: Calculation of a QT interval will be performed throughout subject participation.
Study: NCT00083980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine ER
Description: 75 to 225 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugar pill
Description: Upto 3 per day for venlafainxe and 4 per day for kava placebos.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Upto 3 per day for venlafainxe and 4 per day for kava placebos.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: Upto 3 per day for venlafainxe and 4 per day for kava placebos.
Study: NCT02982031

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: shamrock
Description: This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian transverse scan
Description: The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
Study: NCT01449279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
Study: NCT02208674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized, pharmacist-delivered CKD Action Plan
Description: The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
Study: NCT02500641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80/120mg/day
Description: Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 100 up to 600mg/day
Description: Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg capsules, co-administered to patients for gastric protection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
Study: NCT02017548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-extension default advance directive
Study: NCT02035904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patrol
Description: tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
Study: NCT02017548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort default advance directive
Study: NCT01058720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000 IU orally once daily for 12 weeks
Study: NCT01072474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Capnographic monitoring

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring
Study: NCT00870649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bilhvax vaccine (Sh28GST)
Description: Four vaccine sc administrations over a year associated with chemotherapy (PZQ)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Four placebo sc administrations over a year associated with chemotherapy (PZQ)
Study: NCT01536158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral paracetamol
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Study: NCT00083980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava
Description: 140 to 280 mg per day
Study: NCT02987101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Adipose tissue is harvested by liposuction from either abdomen or thighs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound care
Description: Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Regenerative Cells
Description: Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
Study: NCT00804713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST
Description: 0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST
Description: Administer TB Skin test (TST)
Study: NCT00988858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: 150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
Study: NCT03927820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benefits investigation
Description: The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
Study: NCT00804713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QFT
Description: Perform QFT TB test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-spot
Description: Perform T-Spot TB test
Study: NCT01725321

Intervention type: OTHER
Intervention: Narrow band imaging
Description: Colonoscopy with new narrow band imaging
Study: NCT02527928

Intervention type: OTHER
Intervention: None intervention
Study: NCT02915965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCX
Description: docetaxel, cisplatin and capecitabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Ivor Lewis Esophagectomy
Study: NCT03267875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: draw out 2 blood tubes from a patient
Study: NCT03203486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
Study: NCT00380692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01666197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium 25 mg tablet
Description: diclofenac potassium 25 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo